A Study of the Complete Response Rate with a Combination of High Dose Cytarabine and Cladribine in Refractory and Relapsed Acute Leukemia

Introduction: Acute leukemia covers a broad spectrum of hematological clonal diseases originating from the malignant transformation of stem cells. Current chemotherapeutic methods result in an incomplete response to primary regimens in 30-40% of cases. Methods: 20 patients who had been diagnosed wit...

Full description

Bibliographic Details
Main Authors: Reza Safaei Nodehi, Behrouz Gharib, Ramazaali Sharifian, Amirhossein Emami, Majid Moghadaszadeh, Sara Sardashti
Format: Article
Language:English
Published: Tehran University of Medical Sciences 2010-03-01
Series:International Journal of Hematology-Oncology and Stem Cell Research
Subjects:
Online Access:https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/233
id doaj-c06d92e0679a49cda5103f7cf3fcb6c1
record_format Article
spelling doaj-c06d92e0679a49cda5103f7cf3fcb6c12020-11-25T03:59:14ZengTehran University of Medical SciencesInternational Journal of Hematology-Oncology and Stem Cell Research2008-22072010-03-0141A Study of the Complete Response Rate with a Combination of High Dose Cytarabine and Cladribine in Refractory and Relapsed Acute LeukemiaReza Safaei Nodehi0Behrouz Gharib1Ramazaali Sharifian2Amirhossein Emami3Majid Moghadaszadeh4Sara Sardashti5Tehran University of Medical Sciences- Hematology, Oncology and BMT DepartmentTehran University of Medical Sciences- Hematology and Oncology residentTehran University of Medical Sciences- Hematology, Oncology and BMT DepartmentTehran University of Medical Sciences- Hematology, Oncology and BMT DepartmentTabriz Azad University of Medical Sciences-Tabriz Young Researchers ClubTabriz University of Medical SciencesIntroduction: Acute leukemia covers a broad spectrum of hematological clonal diseases originating from the malignant transformation of stem cells. Current chemotherapeutic methods result in an incomplete response to primary regimens in 30-40% of cases. Methods: 20 patients who had been diagnosed with acute leukemia and who had displayed defined criteria in order to enter our study, were assessed in a clinical trial. A combined chemotherapy regimen with Cladribine and Cytarabine was used in the evaluation of the response to treatment and other parameters between the two ALL (acute lymphoblastic leukemia) and AML (acute myeloid leukemia) groups. Results: Average patient age was 32.5±11.3. 13 patients (65%) were male and 7 patients (35%) were female. The average blast count was 67.7% ±18.3% in the AML group while this count was 63.8±19.6% in the ALL group. 5 out of 11 (45.5%) AML patients and 4 out of 9 ALL patients (44.4%) died during our experiment with no significant statistical difference between the two groups (P=0.65). 4 of the AML patients (36.4%) showed complete response while 4 cases (36.4%) were refractory. In the ALL group, there were 3 patients (33.3%) with complete response and 5 (55.6%) were refractory cases. Conclusion: According to the results of the present study compared to other similar studies, a combined chemotherapy regimen of Cladribine and Cytarabine can be used in acute relapsed and refractory leukemia, however, with high toxicity and high early mortality. If factors are controlled, mortality can be reduced in some cases. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/233Acute LeukemiaChemotherapy RegimenMortality
collection DOAJ
language English
format Article
sources DOAJ
author Reza Safaei Nodehi
Behrouz Gharib
Ramazaali Sharifian
Amirhossein Emami
Majid Moghadaszadeh
Sara Sardashti
spellingShingle Reza Safaei Nodehi
Behrouz Gharib
Ramazaali Sharifian
Amirhossein Emami
Majid Moghadaszadeh
Sara Sardashti
A Study of the Complete Response Rate with a Combination of High Dose Cytarabine and Cladribine in Refractory and Relapsed Acute Leukemia
International Journal of Hematology-Oncology and Stem Cell Research
Acute Leukemia
Chemotherapy Regimen
Mortality
author_facet Reza Safaei Nodehi
Behrouz Gharib
Ramazaali Sharifian
Amirhossein Emami
Majid Moghadaszadeh
Sara Sardashti
author_sort Reza Safaei Nodehi
title A Study of the Complete Response Rate with a Combination of High Dose Cytarabine and Cladribine in Refractory and Relapsed Acute Leukemia
title_short A Study of the Complete Response Rate with a Combination of High Dose Cytarabine and Cladribine in Refractory and Relapsed Acute Leukemia
title_full A Study of the Complete Response Rate with a Combination of High Dose Cytarabine and Cladribine in Refractory and Relapsed Acute Leukemia
title_fullStr A Study of the Complete Response Rate with a Combination of High Dose Cytarabine and Cladribine in Refractory and Relapsed Acute Leukemia
title_full_unstemmed A Study of the Complete Response Rate with a Combination of High Dose Cytarabine and Cladribine in Refractory and Relapsed Acute Leukemia
title_sort study of the complete response rate with a combination of high dose cytarabine and cladribine in refractory and relapsed acute leukemia
publisher Tehran University of Medical Sciences
series International Journal of Hematology-Oncology and Stem Cell Research
issn 2008-2207
publishDate 2010-03-01
description Introduction: Acute leukemia covers a broad spectrum of hematological clonal diseases originating from the malignant transformation of stem cells. Current chemotherapeutic methods result in an incomplete response to primary regimens in 30-40% of cases. Methods: 20 patients who had been diagnosed with acute leukemia and who had displayed defined criteria in order to enter our study, were assessed in a clinical trial. A combined chemotherapy regimen with Cladribine and Cytarabine was used in the evaluation of the response to treatment and other parameters between the two ALL (acute lymphoblastic leukemia) and AML (acute myeloid leukemia) groups. Results: Average patient age was 32.5±11.3. 13 patients (65%) were male and 7 patients (35%) were female. The average blast count was 67.7% ±18.3% in the AML group while this count was 63.8±19.6% in the ALL group. 5 out of 11 (45.5%) AML patients and 4 out of 9 ALL patients (44.4%) died during our experiment with no significant statistical difference between the two groups (P=0.65). 4 of the AML patients (36.4%) showed complete response while 4 cases (36.4%) were refractory. In the ALL group, there were 3 patients (33.3%) with complete response and 5 (55.6%) were refractory cases. Conclusion: According to the results of the present study compared to other similar studies, a combined chemotherapy regimen of Cladribine and Cytarabine can be used in acute relapsed and refractory leukemia, however, with high toxicity and high early mortality. If factors are controlled, mortality can be reduced in some cases.
topic Acute Leukemia
Chemotherapy Regimen
Mortality
url https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/233
work_keys_str_mv AT rezasafaeinodehi astudyofthecompleteresponseratewithacombinationofhighdosecytarabineandcladribineinrefractoryandrelapsedacuteleukemia
AT behrouzgharib astudyofthecompleteresponseratewithacombinationofhighdosecytarabineandcladribineinrefractoryandrelapsedacuteleukemia
AT ramazaalisharifian astudyofthecompleteresponseratewithacombinationofhighdosecytarabineandcladribineinrefractoryandrelapsedacuteleukemia
AT amirhosseinemami astudyofthecompleteresponseratewithacombinationofhighdosecytarabineandcladribineinrefractoryandrelapsedacuteleukemia
AT majidmoghadaszadeh astudyofthecompleteresponseratewithacombinationofhighdosecytarabineandcladribineinrefractoryandrelapsedacuteleukemia
AT sarasardashti astudyofthecompleteresponseratewithacombinationofhighdosecytarabineandcladribineinrefractoryandrelapsedacuteleukemia
AT rezasafaeinodehi studyofthecompleteresponseratewithacombinationofhighdosecytarabineandcladribineinrefractoryandrelapsedacuteleukemia
AT behrouzgharib studyofthecompleteresponseratewithacombinationofhighdosecytarabineandcladribineinrefractoryandrelapsedacuteleukemia
AT ramazaalisharifian studyofthecompleteresponseratewithacombinationofhighdosecytarabineandcladribineinrefractoryandrelapsedacuteleukemia
AT amirhosseinemami studyofthecompleteresponseratewithacombinationofhighdosecytarabineandcladribineinrefractoryandrelapsedacuteleukemia
AT majidmoghadaszadeh studyofthecompleteresponseratewithacombinationofhighdosecytarabineandcladribineinrefractoryandrelapsedacuteleukemia
AT sarasardashti studyofthecompleteresponseratewithacombinationofhighdosecytarabineandcladribineinrefractoryandrelapsedacuteleukemia
_version_ 1724455077187420160